Clinical Trials

Phase 1 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Disease Progression

NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

18 enrolled

BreastGastrointestinalGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT06180356 2025-11-28

ANALLISA

30 enrolled

Ovarian Neoplasms

NCT05009082 2025-09-10

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

Phase 3 Recruiting

970 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03783949 2025-06-11

EUDARIO

Phase 2 Completed

122 enrolled 23 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05672095 2025-05-23

Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer

Phase 1/2 Withdrawn

Phase 1 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04502602 2025-05-04

iNNOVATE

18 enrolled

Ovarian Neoplasms

NCT05990192 2025-04-22

SOPRANO

42 enrolled

Ovarian Neoplasms

NCT05523440 2025-03-28

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

Phase 2 Terminated

7 enrolled

Ovarian Neoplasms, Endometrial Neoplasms

NCT06827353 2025-02-14

OVNI-B

Recruiting

300 enrolled

Classical hematologyGynecologic

Carcinoma, Ovarian Neoplasms

NCT03891576 2025-01-17

Newton

Phase 2 Terminated

83 enrolled

Anemia, Fallopian Tube Neoplasms, Neutropenia, Ovarian Neoplasms, Recurrence, Thrombocytopenia

NCT04507841 2024-12-17

Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Phase 2 Active not recruiting

67 enrolled

Ovarian Neoplasms

NCT03752216 2024-12-13

NiQoLe

Phase 4 Completed

141 enrolled

Ovarian Neoplasms

NCT04826198 2024-12-05

REVOCAN

Phase 1/2 Terminated

13 enrolled

Ovarian Neoplasms

NCT06614790 2024-10-23

NIRAPARIB

Recruiting

300 enrolled

Ovarian Neoplasms

NCT05183984 2024-10-16

NIRVANA-1

390 enrolled

Ovarian Neoplasms

NCT06161493 2024-10-15

ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors

Phase 1 Withdrawn

Ovarian Neoplasms

NCT03598270 2024-08-30

ANITA

Phase 3 Completed

417 enrolled

Phase EARLY_PHASE1 Withdrawn

Ovarian Neoplasms

NCT03154281 2024-08-01

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

Phase 1 Completed

14 enrolled 12 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT05065021 2024-01-17

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

40 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05961124 2023-11-22

Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

40 enrolled

Ovarian Neoplasms

NCT03944902 2023-11-21

BRCA

Phase 1 Terminated

1 enrolled

Ovarian Neoplasms

NCT05749211 2023-05-16

Huaier Granule in Combination With Nilaparil in Therapy Patients With Stage III/IV BRCA Wild-type Ovarian Cancer

Phase NA Unknown

59 enrolled

Ovarian Neoplasms

NCT05734911 2023-02-21

Effectiveness and Safety of Niraparib as First-line Maintenance Therapy for Ovarian Cancer: a Real-world Study

Completed

199 enrolled

Ovarian Neoplasms

NCT05641506 2022-12-07

A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer

50 enrolled

Nausea, Ovarian Neoplasms

NCT02354131 2022-08-30

AVANOVA

Phase 1/2 Completed

108 enrolled

Ovarian Neoplasms

NCT05311579 2022-04-13

Niraparib Plus Anlotinib for Recurrent Ovarian Cancer

36 enrolled

Ovarian Neoplasms

NCT05187208 2022-01-26

POLO

Phase 4 Unknown

102 enrolled

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT04295577 2022-01-21

MONITOR-UK

Unknown

350 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05044091 2021-09-14

HOPEI

Unknown

100 enrolled

Kenny-Caffey syndrome, Type 1, Ovarian Neoplasms

NCT04217798 2021-09-01

Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer

36 enrolled

Ovarian Neoplasms

NCT04679064 2021-08-27

NItCHE-MITO33

Phase 3 Unknown

427 enrolled

Ovarian Neoplasms

NCT03806049 2021-07-15

Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

Phase 3 Withdrawn

Ovarian Neoplasms

NCT04582552 2021-01-20

ROMP

Unknown

60 enrolled

Ovarian Neoplasms

NCT03895788 2019-03-29

A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer

Phase 1 Unknown

24 enrolled